Unknown

Dataset Information

0

Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer.


ABSTRACT: This study explored the clinical implications of tumor mutational burden (TMB) in a well-defined HER2-positive metastatic breast cancer (MBC) patient population who had been previously treated but had subsequent disease progression. Whole exome sequencing was performed on formalin-fixed paraffin-embedded tumor samples and matched normal tissue. Among the 46 patients, 13 (28.3%) were estrogen receptor-positive and nine (19.6%) were progesterone receptor-positive by immunohistochemistry analysis. Twenty patients (43.5%) had recurrent MBC compared with de novo MBC (n = 26, 56.5%). Sixteen patients (34.6%) demonstrated more than 100 somatic non-synonymous SNV mutations, which was predefined as a high TMB. The median follow-up duration was 57.5 months. The median overall survival (mOS) differed significantly between low and high TMB status (44.9 months vs. 85.8 months, respectively, p = 0.016). In a multivariate Cox regression analysis, TMB was the only independent prognostic factor for good metastatic overall survival after adjusting for age and recurrence (Hazard ratio [HR] = 0.32, 95% confidence interval [CI], 0.103-0.998, p = 0.049). These data suggest that high TMB may be a prognostic marker for predicting good overall survival for patients undergoing conventional HER2-directed treatments and chemotherapy. Further, future clinical trials harnessing TMB may benefit by identifying an appropriate population who may have a favorable response to immunotherapy after recurrence following HER2-directed treatments.

SUBMITTER: Park SE 

PROVIDER: S-EPMC6136852 | biostudies-other | 2018

REPOSITORIES: biostudies-other

altmetric image

Publications

Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer.

Park Song Ee SE   Park Kyunghee K   Lee Eunjin E   Kim Ji-Yeon JY   Ahn Jin Seok JS   Im Young-Hyuck YH   Lee Choonghoon C   Jung Hun H   Cho Soo Youn SY   Park Woong-Yang WY   Cristescu Razvan R   Park Yeon Hee YH  

Oncoimmunology 20180524 8


This study explored the clinical implications of tumor mutational burden (TMB) in a well-defined HER2-positive metastatic breast cancer (MBC) patient population who had been previously treated but had subsequent disease progression. Whole exome sequencing was performed on formalin-fixed paraffin-embedded tumor samples and matched normal tissue. Among the 46 patients, 13 (28.3%) were estrogen receptor-positive and nine (19.6%) were progesterone receptor-positive by immunohistochemistry analysis.  ...[more]

Similar Datasets

| S-EPMC4834606 | biostudies-literature
| S-EPMC4895232 | biostudies-literature
| S-EPMC4471111 | biostudies-literature
| S-EPMC4180403 | biostudies-literature
| S-EPMC3643882 | biostudies-other
| S-EPMC6624164 | biostudies-literature
| S-EPMC4741657 | biostudies-literature
| S-EPMC3018524 | biostudies-literature
| S-EPMC5584549 | biostudies-literature
| S-EPMC5947455 | biostudies-literature